News articles about Ohr Pharmaceuticals (NASDAQ:OHRP) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ohr Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.9874918171276 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Shares of Ohr Pharmaceuticals (NASDAQ:OHRP) opened at 0.6199 on Tuesday. The stock has a 50 day moving average of $0.63 and a 200 day moving average of $0.78. Ohr Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $4.05. The company’s market cap is $34.85 million.

Ohr Pharmaceuticals (NASDAQ:OHRP) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.18. On average, equities research analysts expect that Ohr Pharmaceuticals will post ($0.95) EPS for the current year.

Separately, Zacks Investment Research lowered shares of Ohr Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 20th.

WARNING: “Ohr Pharmaceuticals (NASDAQ:OHRP) Receives Daily Media Impact Score of 0.16” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at

Insider Buying and Selling by Quarter for Ohr Pharmaceuticals (NASDAQ:OHRP)

Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.